Risk Factors and Long-term Impact of ICIs

Active, not recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 31, 2025

Conditions
Malignant Neoplasm
Interventions
DRUG

Solid tumor patients receiving immunotherapy for the first time were included in the study

Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy

Trial Locations (1)

710061

First Affiliated Hospitap of Xian Jiaotong University, Xi’an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER